Literature DB >> 26432403

Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression.

David Anz1, Moritz Rapp2, Stephan Eiber1, Viktor H Koelzer2, Raffael Thaler2, Sascha Haubner2, Max Knott2, Sarah Nagel2, Michaela Golic2, Gabriela M Wiedemann2, Franz Bauernfeind3, Cornelia Wurzenberger2, Veit Hornung4, Christoph Scholz5, Doris Mayr6, Simon Rothenfusser2, Stefan Endres7, Carole Bourquin8.   

Abstract

The chemokine CCL22 is abundantly expressed in many types of cancer and is instrumental for intratumoral recruitment of regulatory T cells (Treg), an important subset of immunosuppressive and tumor-promoting lymphocytes. In this study, we offer evidence for a generalized strategy to blunt Treg activity that can limit immune escape and promote tumor rejection. Activation of innate immunity with Toll-like receptor (TLR) or RIG-I-like receptor (RLR) ligands prevented accumulation of Treg in tumors by blocking their immigration. Mechanistic investigations indicated that Treg blockade was a consequence of reduced intratumoral CCL22 levels caused by type I IFN. Notably, stable expression of CCL22 abrogated the antitumor effects of treatment with RLR or TLR ligands. Taken together, our findings argue that type I IFN blocks the Treg-attracting chemokine CCL22 and thus helps limit the recruitment of Treg to tumors, a finding with implications for cancer immunotherapy. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26432403     DOI: 10.1158/0008-5472.CAN-14-3499

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

Review 1.  Guidance factors orchestrating regulatory T cell positioning in tissues during development, homeostasis, and response.

Authors:  Thorsten R Mempel; Francesco Marangoni
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

2.  Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.

Authors:  Patricia A Young; Reiko E Yamada; Kham R Trinh; Alex Vasuthasawat; Satiro De Oliveira; Douglas H Yamada; Sherie L Morrison; John M Timmerman
Journal:  J Interferon Cytokine Res       Date:  2018-06       Impact factor: 2.607

3.  C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer.

Authors:  Songyang Wu; Hongyong He; Hao Liu; Yifan Cao; Rochen Li; Heng Zhang; He Li; Zhenbin Shen; Jing Qin; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-03-06       Impact factor: 8.110

4.  Ewing Sarcoma-Specific (Re)expression Models.

Authors:  Maximilian M L Knott; Florencia Cidre-Aranaz
Journal:  Methods Mol Biol       Date:  2021

5.  CCL22-Polarized TAMs to M2a Macrophages in Cervical Cancer In Vitro Model.

Authors:  Qun Wang; Kritika Sudan; Elisa Schmoeckel; Bernd Peter Kost; Christina Kuhn; Aurelia Vattai; Theresa Vilsmaier; Sven Mahner; Udo Jeschke; Helene Hildegard Heidegger
Journal:  Cells       Date:  2022-06-25       Impact factor: 7.666

6.  Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells.

Authors:  Gabriela Maria Wiedemann; Max Martin Ludwig Knott; Viola Katharina Vetter; Moritz Rapp; Sascha Haubner; Julia Fesseler; Benjamin Kühnemuth; Patrick Layritz; Raffael Thaler; Stephan Kruger; Steffen Ormanns; Doris Mayr; Stefan Endres; David Anz
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

7.  Fucoidan inhibits CCL22 production through NF-κB pathway in M2 macrophages: a potential therapeutic strategy for cancer.

Authors:  Jia Sun; Jintang Sun; Bingfeng Song; Lin Zhang; Qianqian Shao; Yanguo Liu; Daoying Yuan; Yun Zhang; Xun Qu
Journal:  Sci Rep       Date:  2016-10-24       Impact factor: 4.379

Review 8.  Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".

Authors:  Michael Karl Melzer; Arturo Lopez-Martinez; Jennifer Altomonte
Journal:  Biomedicines       Date:  2017-02-10

9.  C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer.

Authors:  Moritz Rapp; Simon Grassmann; Michael Chaloupka; Patrick Layritz; Stephan Kruger; Steffen Ormanns; Felicitas Rataj; Klaus-Peter Janssen; Stefan Endres; David Anz; Sebastian Kobold
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

10.  Global Regulatory T-Cell Research from 2000 to 2015: A Bibliometric Analysis.

Authors:  Yin Zongyi; Chen Dongying; Li Baifeng
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.